Mesothelioma is a rare and aggressive cancer caused by asbestos exposure, accounting for merely 0.17% of total estimated cancer cases. It presents as pleural, peritoneal, pericardial, and testicular mesothelioma. There is a high unmet clinical need for better therapies, as current treatment options, such as chemotherapy and radiation, offer limited efficacy. The pipeline for mesothelioma therapeutics is expanding with novel immunotherapies, targeted therapies, and gene-based treatments. The rising focus on personalized medicine and innovative drug development is likely to support pipeline growth in the coming years, offering hope for improved patient outcomes.
Major companies involved in the mesothelioma pipeline drugs market include Novartis Pharmaceuticals, Bristol-Myers Squibb, and others.
Leading drugs currently in the pipeline include Tremelimumab, IAG933, and others.
The rising advancements in immunotherapy and targeted treatments, increased research funding, and a growing focus on personalized medicine are driving the expansion of the mesothelioma pipeline landscape.
The Mesothelioma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into mesothelioma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for mesothelioma. The mesothelioma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The mesothelioma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with mesothelioma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to mesothelioma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Mesothelioma is a rare, aggressive cancer that develops in the mesothelial cells lining the lungs, abdomen, or heart. It is primarily caused by asbestos exposure, which leads to inflammation and genetic mutations over time. Symptoms often appear decades after exposure, making early diagnosis challenging.
Mesothelioma treatment includes surgery, chemotherapy, and radiation therapy. These options aim to control symptoms, reduce tumor size, and prolong survival. Emerging immunotherapies and targeted treatments are showing promise, offering hope for better outcomes in the future.
Mesothelioma, a rare cancer accounting for only 0.17% of all cancer cases, witnesses around 3,000 new diagnoses annually in the United States, affecting roughly 1 in 100,000 individuals. In the United Kingdom, it ranks as the 19th most common cause of cancer death, contributing to 1% of all cancer-related fatalities. The ongoing development of mesothelioma therapeutics is crucial in addressing the current medical needs.
This section of the report covers the analysis of mesothelioma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I accounts for a major share of the total mesothelioma clinical trials.
The drug molecule categories covered in the mesothelioma pipeline analysis include small molecules, monoclonal antibodies, CAR-T cell therapies, gene therapies, RNA-based therapies, and others. The mesothelioma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for mesothelioma.
The EMR report for the mesothelioma drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed mesothelioma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in mesothelioma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for mesothelioma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of mesothelioma drug candidates.
The DREAM3R trial, sponsored by PrECOG, LLC, aims to assess whether adding durvalumab to standard chemotherapy enhances overall survival in advanced pleural mesothelioma patients. This Phase III study will involve about 214 participants and will compare durvalumab plus chemotherapy versus physician-chosen treatment. It is expected to be completed by February 2026.
MedImmune LLC is sponsoring a Phase IIb randomized, double-blind study evaluating Tremelimumab for unresectable pleural or peritoneal malignant mesothelioma. The objective is to assess its efficacy and safety compared to a placebo. The trial involves around 571 participants across multiple countries and is expected to conclude by April 2025.
A Phase I study, sponsored by Novartis Pharmaceuticals, aims to evaluate the safety and tolerability of IAG933 in advanced mesothelioma and other solid tumors. This trial aims to determine the maximum tolerated dose and recommended dosage. The study is expected to conclude by September 2026 and will involve approximately 156 participants across multiple centers.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Mesothelioma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for mesothelioma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into mesothelioma collaborations, regulatory environments, and potential growth opportunities.
Global Cancer Screening Market
Global Malignant Mesothelioma Therapeutics Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share